Cellply secures €7.15 million in funding and opens round extension to accelerate global expansion

BOLOGNA, Italy — April 23, 2026 — Cellply, a pioneer in deep functional cell analysis, today announced the completion of the largest portion of its latest funding round, securing €7.15 million to date in the largest financing round completed by the company to date. The investment was led by ENEA Tech e Biomedical, with additional participation from existing shareholders, including the SAFE conversion into equity by CDP Venture Capital (through its Fondo Rilancio). A limited final allocation remains available to selected investors. The financing marks a pivotal milestone in the company’s mission to shape the future of advanced therapies (ATMPs), including cell and gene therapies and regenerative medicine. 

With this fresh capital, Cellply will focus on two immediate strategic priorities. First, the company will accelerate the international expansion of its flagship VivaCyte® platform, increasing commercial presence across key global markets.  Second, Cellply will advance the development of next-generation automated functional testing solutions for ATMP quality control, aimed at delivering unprecedented precision in cell potency assessment while streamlining batch release.

“We are pleased to welcome Enea Tech and Biomedical Foundation as lead investor and to strengthen our shareholder base with the support of CDP Venture Capital and our existing investors” said Alessia Zanelli, President and CEO at Cellply. “This investment provides the resources to accelerate our commercial expansion and advance innovative quality control solutions that can help unlock broader adoption of ATMPs worldwide.”

In conjunction with the funding, Cellply has strengthened its leadership team by welcoming Miro Venturi to its Board of Directors, an esteemed industry veteran who made significant contributions to precision medicine at scale and brings decades of experience in global diagnostics, life sciences and corporate leadership.

Miro Venturi commented: “I am excited to join Cellply’s Board at such an important stage of the company’s journey. Cellply has built a highly differentiated technology platform addressing critical unmet needs in one of the most promising areas of healthcare innovation, supported by a top-notch team with strong capabilities in science and technology. I look forward to supporting the management team as they scale internationally, expand commercial adoption of VivaCyte, and advance new solutions for quality control in advanced therapies.”

Cellply’s long-term ambition is to be the global leader in analytical tools for research and quality control within the cell therapy and regenerative medicine sectors. As the industry advances toward increasingly complex and personalized medicines, robust and standardized functional assays will become fundamental to enable scalability, sustainability, and broader patient access.

About Cellply

Cellply is a biology-focused deep tech company developing tools to unravel the complexity of the immune system and enable rapid development of new immunotherapies and cell-based therapies with enhanced potency and persistence. Headquartered in Bologna, Italy, the team is creating state-of-the-art analytical solutions capable of robustly characterizing these exciting therapeutic modalities at single-cell resolution.  Cellply has combined patented microfluidic technology and AI-powered automated image analysis capability with comprehensive automation and dedicated software to create its flagship product VivaCyte^®. Today Cellply is focused on enhancing research and development of cell therapies. Tomorrow its ambition is to dramatically reduce cost and complexity of batch release and potency assays in quality control for these promising innovative therapies.

To find out more visit: cellply.com

Media Contact: press@cellply.com